Article(id=1322127316378039114, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322127297054888908, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1619193600000, acceptedDateStr=2021-04-24, onlineDate=1793149316161, onlineDateStr=2026-10-28, pubDate=1639497600000, pubDateStr=2021-12-15, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793149316161, onlineIssueDateStr=2026-10-28, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793149316161, creator=13701087609, updateTime=1793149316161, updator=13701087609, issue=Issue{id=1322127297054888908, tenantId=1146029695717560320, journalId=1235980733773295621, year='2021', volume='30', issue='23', pageStart='2121', pageEnd='2224', issueExtLink='null', onlineDate='null', pubDate='1639497600000', pubDateStr='2021-12-15', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793149311555, creator='13701087609', updateTime=1793149538282, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1322128248071369266, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322127297054888908, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1322128248075563571, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322127297054888908, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=2178, endPage=2188, ext={EN=ArticleExt(id=1322127316612920139, articleId=1322127316378039114, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=Research progress of small-molecule Janus kinase inhibitors, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Janus kinases (JAKs) are a class of non-receptor tyrosine kinases. In the past two decades, small-molecule Janus kinases inhibitors have gradually entered the public vision and received extensive attention from researchers. JAKs can regulate cell proliferation, differentiation, apoptosis, angiogenesis and immunity through JAK-STAT signal pathway formed by Janus kinases and their downstream signal transducers and activators of transcription. The inhibitors of JAKs can be used for prevention and treatment of autoimmune diseases, inflammatory reactions and malignant tumors. At present, nearly ten small-molecule Janus kinases inhibitors have been approved for marketing, and some others are in clinical research stage. This review summarizes the structure of Janus kinase, JAK-STAT signaling pathway, research and development progress and clinical application of JAKs inhibitors in recent years, providing useful reference for the further research and development of this class of inhibitors.

, authors=Meng-li LI, Cheng LU, Hui-yang WAN, Yu-bin WANG, authorsList=Meng-li LI, Cheng LU, Hui-yang WAN, Yu-bin WANG, authorCompany=null, correspAuthors=Yu-bin WANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1322127316944270156, articleId=1322127316378039114, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=小分子Janus激酶抑制剂的研究进展, columnId=1236330553964810454, journalTitle=中国新药杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

Janus激酶（JAKs）是一类非受体型酪氨酸激酶，在过去近20年里，小分子Janus激酶抑制剂逐渐进入大众视野并受到研究者广泛的重视。JAKs可通过其与下游的信号传导及转录激活因子形成的JAK-STAT信号通路调节细胞增殖、分化、凋亡以及血管生成和免疫，其抑制剂可用于自身免疫性疾病、炎症反应以及恶性肿瘤等的防治。目前已经有近10种小分子Janus激酶抑制剂获得上市资格，还有一些抑制剂正处于临床研究阶段。本文就Janus激酶的结构、JAK-STAT信号通路以及近年来在研及已上市的JAKs抑制剂的研发进展及临床应用进行综述，旨在为该类抑制剂的研发提供有益的参考。

, authors=李梦丽, 卢诚, 万慧阳, 王玉斌, authorsList=李梦丽, 卢诚, 万慧阳, 王玉斌, authorCompany=null, correspAuthors=王玉斌, authorNote=, correspAuthorsNote=, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=08mKQRyFxJEtFCuNPlwOsw==, magXml=XiGjF81odZzAolRz7HtpAA==, pdfUrl=null, pdf=z/vhmZnnQVsw8cWK1r12nw==, pdfFileSize=3624473, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=YcjLHXODD6HqionMALNaJg==, mapNumber=null, fund=null)}, authors=[Author(id=1322127317309174609, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=1803829113@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322127317569221459, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, authorId=1322127317309174609, language=EN, stringName=Meng-li LI, firstName=Meng-li, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=School of Pharmacy, Nanjing University of Technology, Nanjing 210009, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322127317976068948, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, authorId=1322127317309174609, language=CN, stringName=李梦丽, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京工业大学药学院，南京　210009, bio={"content":"

李梦丽，女，硕士研究生，研究方向：小分子免疫抑制剂的设计、合成与生物学活性评价。E-mail：1803829113@qq.com。

"}, bioImg=null, bioContent=

李梦丽，女，硕士研究生，研究方向：小分子免疫抑制剂的设计、合成与生物学活性评价。E-mail：1803829113@qq.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322127317204317005, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, xref=null, ext=[AuthorCompanyExt(id=1322127317221094222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing University of Technology, Nanjing 210009, China), AuthorCompanyExt(id=1322127317229482831, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京工业大学药学院，南京　210009)])]), Author(id=1322127318072537942, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322127318164812632, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, authorId=1322127318072537942, language=EN, stringName=Cheng LU, firstName=Cheng, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=School of Pharmacy, Nanjing University of Technology, Nanjing 210009, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322127318387110745, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, authorId=1322127318072537942, language=CN, stringName=卢诚, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京工业大学药学院，南京　210009, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322127317204317005, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, xref=null, ext=[AuthorCompanyExt(id=1322127317221094222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing University of Technology, Nanjing 210009, China), AuthorCompanyExt(id=1322127317229482831, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京工业大学药学院，南京　210009)])]), Author(id=1322127318512939867, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322127318668129117, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, authorId=1322127318512939867, language=EN, stringName=Hui-yang WAN, firstName=Hui-yang, middleName=null, lastName=WAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=School of Pharmacy, Nanjing University of Technology, Nanjing 210009, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322127318806541150, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, authorId=1322127318512939867, language=CN, stringName=万慧阳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京工业大学药学院，南京　210009, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322127317204317005, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, xref=null, ext=[AuthorCompanyExt(id=1322127317221094222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing University of Technology, Nanjing 210009, China), AuthorCompanyExt(id=1322127317229482831, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京工业大学药学院，南京　210009)])]), Author(id=1322127318865261408, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=njutwyb5393@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322127318965924706, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, authorId=1322127318865261408, language=EN, stringName=Yu-bin WANG, firstName=Yu-bin, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=School of Pharmacy, Nanjing University of Technology, Nanjing 210009, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322127319033033571, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, authorId=1322127318865261408, language=CN, stringName=王玉斌, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京工业大学药学院，南京　210009, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322127317204317005, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, xref=null, ext=[AuthorCompanyExt(id=1322127317221094222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing University of Technology, Nanjing 210009, China), AuthorCompanyExt(id=1322127317229482831, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京工业大学药学院，南京　210009)])])], keywords=[Keyword(id=1322127319125308260, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, language=EN, orderNo=1, keyword=Janus kinases), Keyword(id=1322127319196611429, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, language=EN, orderNo=2, keyword=JAK-STAT signaling pathway), Keyword(id=1322127319259525990, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, language=EN, orderNo=3, keyword=JAKs inhibitors), Keyword(id=1322127319339217767, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, language=EN, orderNo=4, keyword=research progress), Keyword(id=1322127319410520936, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, language=CN, orderNo=1, keyword=Janus激酶), Keyword(id=1322127319477629801, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, language=CN, orderNo=2, keyword=JAK-STAT通路), Keyword(id=1322127319557321578, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, language=CN, orderNo=3, keyword=JAKs抑制剂), Keyword(id=1322127319670567787, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, language=CN, orderNo=4, keyword=研究进展)], refs=[Reference(id=1322127319771231084, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=SENKEVITCH E, DURUM S. The promise of Janus kinase inhibitors in the treatment of hematological malignancies[J]. Cytokine, 2017, 98: 33-41., articleTitle=null, refAbstract=null), Reference(id=1322127319842534253, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=BABON JJ, LUCET IS, MURPHY JM, et al. The molecular regulation of Janus kinase (JAK) activation[J]. Biochem J, 2014, 462(1): 1-13., articleTitle=null, refAbstract=null), Reference(id=1322127319926420334, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=SAHARINEN P, SILVENNOINEN O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction[J]. J Biol Chem, 2002, 277(49): 47954-47963., articleTitle=null, refAbstract=null), Reference(id=1322127320022889327, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=RADTKE S, HAAN S, JÖRISSEN A, et al. The Jak1 SH₂ domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression[J]. J Biol Chem, 2005, 280(27): 25760-25768., articleTitle=null, refAbstract=null), Reference(id=1322127320110969712, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=COSKUN M, SALEM M, PEDERSEN J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease[J]. Pharmacol Res, 2013, 76: 1-8., articleTitle=null, refAbstract=null), Reference(id=1322127320178078577, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=FENSOME A, AMBLER CM, ARNOLD E, et al. Dual Inhibition of TYK₂ and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2, 2-Difluorocyclopropyl)((1R, 5S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3, 8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)[J]. J Med Chem, 2018, 61(19): 8597-8612., articleTitle=null, refAbstract=null), Reference(id=1322127320341656434, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=FLANAGAN ME, BLUMENKOPF TA, BRISSETTE WH, et al. Discovery of CP-690, 550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection[J]. J Med Chem, 2010, 53(24): 8468-8484., articleTitle=null, refAbstract=null), Reference(id=1322127320450708339, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=SINGH JA, SAAG KG, BRIDGES SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis[J]. Arthritis Care Res (Hoboken), 2016, 68(1): 1-25., articleTitle=null, refAbstract=null), Reference(id=1322127320542983028, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=ARANA YI C, TAM CS, VERSTOVSEK S. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis[J]. Future Oncol, 2015, 11(5): 719-733., articleTitle=null, refAbstract=null), Reference(id=1322127320677200759, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=SAEED I, MCLORNAN D, HARRISON CN. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice[J]. Expert Rev Hematol, 2017, 10(7): 617-625., articleTitle=null, refAbstract=null), Reference(id=1322127320844972920, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=FRIDMAN JS, SCHERLE PA, COLLINS R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050[J]. J Immunol, 2010, 184(9): 5298-5307., articleTitle=null, refAbstract=null), Reference(id=1322127320928859001, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=PAPP KA, MENTER MA, RAMAN M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis[J]. Br J Dermatol, 2016, 174(6): 1266-1276., articleTitle=null, refAbstract=null), Reference(id=1322127321088242554, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=SIMPSON EL, LACOUR JP, SPELMAN L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials[J]. Br J Dermatol, 2020, 183(2): 242-255., articleTitle=null, refAbstract=null), Reference(id=1322127321180517243, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=NOJI S, HARA Y, MIURA T, et al. Discovery of a Janus kinase inhibitor bearing a highly three-dimensional spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders[J]. J Med Chem, 2020, 63(13): 7163-7185., articleTitle=null, refAbstract=null), Reference(id=1322127321318929276, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=TANIMOTO A, SHINOZAKI Y, YAMAMOTO Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents[J]. Exp Dermatol, 2018, 27(1): 22-29., articleTitle=null, refAbstract=null), Reference(id=1322127321394426749, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=HAMAGUCHI H, AMANO Y, MORITOMO A, et al. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor[J]. Bioorg Med Chem, 2018, 26(18): 4971-4983., articleTitle=null, refAbstract=null), Reference(id=1322127321474118526, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=SANDS BE, SANDBORN WJ, FEAGAN BG, et al. Peficitinib, an oral Janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study[J]. J Crohns Colitis, 2018, 12(10): 1158-1169., articleTitle=null, refAbstract=null), Reference(id=1322127321537033087, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=PARDANANI A, LASHO T, SMITH G, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients[J]. Leukemia, 2009, 23(8): 1441-1445., articleTitle=null, refAbstract=null), Reference(id=1322127321612530560, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHENG J, XIN Y, ZHANG JY, et al. Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development[J]. Drug Metab Dispos, 2018, 46(3): 237-247., articleTitle=null, refAbstract=null), Reference(id=1322127321734165377, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=ASSHOFF M, PETZER V, WARR MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates Anemia of chronic disease in rodents[J]. Blood, 2017, 129(13): 1823-1830., articleTitle=null, refAbstract=null), Reference(id=1322127321834828674, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=VAZQUEZ ML, KAILA N, STROHBACH JW, et al. Identification of N-{Cis-3-[methyl(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases[J]. J Med Chem, 2018, 61(3): 1130-1152., articleTitle=null, refAbstract=null), Reference(id=1322127321948074883, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=PARMENTIER JM, VOSS J, GRAFF C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)[J]. BMC Rheumatol, 2018, 2(12): 3141-3154., articleTitle=null, refAbstract=null), Reference(id=1322127322044543876, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=SANDBORN WJ, GHOSH S, PANES J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis[J]. Gastroenterology, 2020, 158(8): 2139-2149., articleTitle=null, refAbstract=null), Reference(id=1322127322136818565, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=SANDBORN WJ, FEAGAN BG, LOFTUS EV, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease[J]. Gastroenterology, 2020, 158(8): 2123-2138., articleTitle=null, refAbstract=null), Reference(id=1322127322250064774, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=GUTTMAN-YASSKY E, THAÇI D, PANGAN AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2020, 145(3): 877-884., articleTitle=null, refAbstract=null), Reference(id=1322127322325562247, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=SILVERBERG JI, SIMPSON EL, THYSSEN JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial[J]. JAMA Dermatol, 2020, 156(8): 863-873., articleTitle=null, refAbstract=null), Reference(id=1322127322417836936, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=MENET CJ, FLETCHER SR, VAN LOMMEN G, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634[J]. J Med Chem, 2014, 57(22): 9323-9342., articleTitle=null, refAbstract=null), Reference(id=1322127322493334409, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=LUDBROOK VJ, HICKS KJ, HANROTT KE, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study[J]. Br J Dermatol, 2016, 174(5): 985-995., articleTitle=null, refAbstract=null), Reference(id=1322127322585609098, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=KAHL L, PATEL J, LAYTON M, et al. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus[J]. Lupus, 2016, 25(13): 1420-1430., articleTitle=null, refAbstract=null), Reference(id=1322127322665300875, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=VAN VOLLENHOVEN RF, LAYTON M, KAHL L, et al. DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184[J]. Lupus, 2015, 24(6): 648-649., articleTitle=null, refAbstract=null), Reference(id=1322127322753381260, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=GONG X, DARPO B, XUE H, et al. Evaluation of clinical cardiac safety of itacitinib, a JAK1 inhibitor, in healthy participants[J]. Clin Pharmacol Drug Dev, 2020, 9(6): 677-688., articleTitle=null, refAbstract=null), Reference(id=1322127322833073037, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=SU QB, ERICA B, GERALDINE B, et al. Discovery of (2R)-N-[3-[2-[(3-methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor[J]. J Med Chem, 2020, 63(9): 4517-4527., articleTitle=null, refAbstract=null), Reference(id=1322127322904376206, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=GHORESCHI K, LAURENCE A, O'SHEA JJ. Janus kinases in immune cell signaling[J]. Immunol Rev, 2009, 228(1): 273-287., articleTitle=null, refAbstract=null), Reference(id=1322127322979873679, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=RAMPAL R, AL-SHAHROUR F, ABDEL-WAHAB O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis[J]. Blood, 2014, 123(22): e123-e133., articleTitle=null, refAbstract=null), Reference(id=1322127323093119888, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=WILLIAM AD, LEE ACH, BLANCHARD S, et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5, 7, 26-triaza-tetracyclo[19.3.1.1(2, 6).1(8, 12)]heptacosa-1(25), 2(26), 3, 5, 8, 10, 12(27), 16, 21, 23-decaene (SB1518), a potent Janus kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma[J]. J Med Chem, 2011, 54(13): 4638-4658., articleTitle=null, refAbstract=null), Reference(id=1322127323168617361, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=VERSTOVSEK S, ODENIKE O, SINGER JW, et al. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies[J]. J Hematol Oncol, 2016, 9(4): 1933-1940., articleTitle=null, refAbstract=null), Reference(id=1322127323269280658, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=TREMBLAY D, MASCARENHAS J. Pacritinib to treat myelofibrosis patients with thrombocytopenia[J]. Expert Rev Hematol, 2018, 11(9): 707-714., articleTitle=null, refAbstract=null), Reference(id=1322127323474801555, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=HARRISON CN, SCHAAP N, MESA RA. Management of myelofibrosis after ruxolitinib failure[J]. Ann Hematol, 2020, 99(6): 1177-1191., articleTitle=null, refAbstract=null), Reference(id=1322127323541910420, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=PARDANANI A, GOTLIB JR, JAMIESON C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis[J]. J Clin Oncol, 2011, 29(7): 789-796., articleTitle=null, refAbstract=null), Reference(id=1322127323613213589, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=VILLA A, SIRONI M, MACCHI P, et al. Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene[J]. Blood, 1996, 88(3): 817-823., articleTitle=null, refAbstract=null), Reference(id=1322127323688711062, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=FARMER LJ, LEDEBOER MW, HOOCK T, et al. Discovery of VX-509 (decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases[J]. J Med Chem, 2015, 58(18): 7195-7216., articleTitle=null, refAbstract=null), Reference(id=1322127323785180055, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=GENOVESE MC, VAN VOLLENHOVEN RF, PACHECO-TENA C, et al. VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis[J]. Arthritis Rheumatol, 2016, 68(1): 46-55., articleTitle=null, refAbstract=null), Reference(id=1322127323881649048, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=THORARENSEN A, DOWTY ME, BANKER ME, et al. Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2S, 5R)-5-((7H-Pyrrolo[2, 3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans[J]. J Med Chem, 2017, 60(5): 1971-1993., articleTitle=null, refAbstract=null), Reference(id=1322127323957146521, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=KREINS AY, CIANCANELLI MJ, OKADA S, et al. Human TYK₂ deficiency: mycobacterial and viral infections without hyper-IgE syndrome[J]. J Exp Med, 2015, 212(10): 1641-1662., articleTitle=null, refAbstract=null), Reference(id=1322127324120724378, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=NOGUEIRA M, PUIG L, TORRES T. JAK inhibitors for treatment of psoriasis: focus on selective TYK₂ inhibitors[J]. Drugs, 2020, 80(4): 341-352., articleTitle=null, refAbstract=null), Reference(id=1322127324309468059, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=HAWKES JE, YAN BY, CHAN TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis[J]. J Immunol, 2018, 201(6): 1605-1613., articleTitle=null, refAbstract=null), Reference(id=1322127324468851612, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=WROBLESKI ST, MOSLIN R, LIN S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK₂) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165[J]. J Med Chem, 2019, 62(20): 8973-8995., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1322127317204317005, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, xref=null, ext=[AuthorCompanyExt(id=1322127317221094222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Pharmacy, Nanjing University of Technology, Nanjing 210009, China), AuthorCompanyExt(id=1322127317229482831, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127316378039114, companyId=1322127317204317005, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京工业大学药学院，南京　210009)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1788948968376, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509780974924039, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968404, updatedTime=1788948968404, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509781025255688, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968416, updatedTime=1788948968416, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2021/V30/I23/2178, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2021/V30/I23/2178, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2021/V30/I23/2178, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2021/V30/I23/2178, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1639497600000, fullTextJson=null, articleText=null, reference=null)